# Mechanisms Underlying Heterogeneity of Cognitive Outcomes in Synucleinopathy

> **NIH NIH P01** · UNIVERSITY OF PENNSYLVANIA · 2024 · $3,852,175

## Abstract

OVERALL ABSTRACT/SUMMARY
The mission of this Penn PO1 Center on “Mechanisms underlying heterogeneity of cognitive outcome in
synucleinopathy” is to understand why the same underlying core pathology – inclusions of alpha-synuclein
(aSyn) – varies so widely in the pace and pattern of spread within the brain, resulting in dramatically divergent
clinical trajectories. The Lewy body disorders (LBD) – namely, dementia with Lewy bodies (DLB), Parkinson’s
disease (PD), and Alzheimer’s disease with Lewy bodies (LBD+AD) – share the core feature of neuronal aSyn
inclusions. However, patients manifest very differently from one another, with differences in cognition playing a
vital role with respect to patient quality of life and cost to the healthcare system. Because the LBD affect so
many, with no FDA-approved disease-modifying therapies, they constitute one of the most important Alzheimer’s
Disease Related Dementias (ADRD) affecting the world today. This PO1 Center hypothesizes that several key
features play fundamental roles in determining whether a given LBD individual might develop dementia from the
outset, after a few years, after many decades, or not at all. These features are: (1) the interplay of aSyn with -
amyloid plaques and tau neurofibrillary tangles, (2) the conformation of aSyn, (3) host genomics and proteomics,
and (4) the locus/entry point of early pathology. We test this hypothesis in four synergistic Research Projects.
Project I investigates the role of concomitant -amyloid and tau pathology in governing patterns of aSyn spread
in human postmortem brain. Project II characterizes human brain-derived aSyn strains with cryo-ET and cell
biological techniques. Project III leverages genomic and biomarker data to derive candidate molecular players,
then manipulates these genes/proteins in neurons to understand their role in the uptake of fibrillar aSyn,
development of aSyn pathology, and cell-to-cell transmission of aSyn pathology. Project IV extends our
investigations of host factors to mouse models, testing the role of genetic background, route of aSyn exposure,
and type of aSyn strain in modulating in vivo pathological aSyn spread. All four research projects focus on
mechanisms, grounded in human data, and they are supported by four Cores that (1) serve Administrative
functions, (2) recruit Clinical patients, (3) provide biosample Resources to Research Projects and to external
investigators, and (4) manage Data for Research Projects and sharing to external investigators. Thus, the Penn
PO1 Center seeks to discover and develop new therapeutic strategies to delay or prevent dementia in the LBD.

## Key facts

- **NIH application ID:** 10935304
- **Project number:** 1P01AG084497-01A1
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** ALICE S CHEN-PLOTKIN
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $3,852,175
- **Award type:** 1
- **Project period:** 2024-09-15 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10935304

## Citation

> US National Institutes of Health, RePORTER application 10935304, Mechanisms Underlying Heterogeneity of Cognitive Outcomes in Synucleinopathy (1P01AG084497-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10935304. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*